Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow

American Journal of Physiology - Endocrinology and Metabolism

Volumn 298, Issue 3, 2010, Pages

  Sanz, C ^a,b   Vazquez P ^a,b,c   Blazquez C ^d,e   Barrio, P A ^a,b   Alvarez, M Del M ^a   Blazquez E ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL DE JEREZ   (Spain)

Author keywords

Adipogenesis; Cytoprotection; Human mesenchymal stem cell; Proliferation

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CELL MARKER; CYCLINE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIPOPROTEIN LIPASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 2;

ADIPOCYTE; ADIPOGENESIS; ADULT; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADULT; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED;

EID: 77349116804     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00460.2009     Document Type: Article

References (42)

1. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57: 1759-1767, 2008.
2. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Caceres J, Desco M, Pozo MA, Blazquez E. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92: 798-806, 2005.
3. Alvarez E, Roncero I, Chowen JA, Thorens B, Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66: 920-927, 1996.
4. Bost F, Aouadi M, Caron L, Binétruy, B. The role of MAPKs in adipocyte differentiation and obesity: new developments in metabolic syndrome. Biochimie 87: 51-56, 2005.
5. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros L, Di Mario U, Perfetti R. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29: 347-360, 2002.
6. Chowen JA, de Fonseca FR, Alvarez E, Navarro M, García-Segura LM, Blázquez E. Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain. Neuropeptides 33: 212-215, 1999.
7. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100: 6825-6830, 2003.
8. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52: 365-371, 2003.
9. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396: 474-477, 1998.
10. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17: 161-171, 2003.
11. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179, 2003.
12. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158, 2003.
13. Fleming I, MacKenzie SJ, Vernon RG, Anderson NG, Houslay MD, Kilgour E. Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation. Biochem J 333: 719-727, 1998.
14. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 131: 242-256, 2007.
15. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 122: S11-S24, 2009.
16. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 78: 783-809, 1998.
17. Gressens P, Paindaveine B, Hill JM, Brenneman DE, Evrard P. Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies. Ann NY Acad Sci 814: 152-160, 1997.
18. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322, 1992.
19. Hauner H. Obesity and diabetes-potential for intervention? J Endocrinol 155: 223, 1997.
20. Hauner H, Rohrig K, Petruschke T. Effects of epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) on human adipocyte development and function. Eur J Clin Invest 25: 90-96, 1995.
21. Hirsch J, Fried SK, Edens NK, Leibel RL. The fat cell. Med Clin North Am 73: 83-96, 1989.
22. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274: 2100-2103, 1996.
23. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate Rap1. Science 282: 2275-2279, 1998.
24. Klinger S, Poussin C, Debril MB, Dolci W, Halban PA, Thorens B. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 57: 584-593, 2008.
25. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
26. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003.
27. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54: 2212-2218, 2005.
28. Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blázquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67: 1982-1991, 1996.
29. Navre M, Ringold GM. Differential effects of fibroblast growth factor and tumor promoters on the initiation and maintenance of adipocyte differentiation. J Cell Biol 109: 1857-1863, 1989.
30. Pittenger MF, Mackay A, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999.
31. Romero-Prado M, Blázquez C, Rodríguez-Navas C, Muñoz J, Guerrero I, Delgado-Baeza E, García-Ruiz JP. Functional characterization of human mesenchymal stem cells that maintain osteochondral fates. J Cell Biochem 98: 1457-1470, 2006.
32. Ron D, Brasier AR, McGehee RE Jr, Habener JF. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest 89: 223-233, 1992.
33. Sancho V, Trigo MV, Martín-Duce A, Gonz Lez N, Acitores A, Arnés L, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 17: 1133-1137, 2006.
34. Sanz C, Leon Y, Canon S, Alvarez L, Giraldez F, Varela-Nieto I. Pattern of expression of the jun family of transcription factors during the early development of the inner ear: implications in apoptosis. J Cell Sci 112: 3967-3974, 1999.
35. Sanz C, Leon Y, Troppmair J, Rapp UR, Varela-Nieto I. Strict regulation of c-Raf kinase levels is required for early organogenesis of the vertebrate inner ear. Oncogene 18: 429-437, 1999.
36. Sanz C, Roncero I, Vázquez P, Navas MA, Blázquez E. Effects of glucose and insulin on glucokinase activity in rat hypothalamus. J Endocrinol 193: 259-267, 2007.
37. Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison WO, Halvorsen YD, Gimble JM. Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. J Cell Biochem 81: 312-319, 2001.
38. Serrero G, Mills D. Physiological role of epidermal growth factor on adipose tissue development in vivo. Proc Natl Acad Sci USA 88: 3912-3916, 1991.
39. Tang DQ, Cao LZ, Burkhardt BR, Xia CQ, Litherland SA, Atkinson MA, Yang LJ. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 53: 1721-1732, 2004.
40. Torti FM, Torti SV, Larrick JW, Ringold GM. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta. J Cell Biol 108: 1105-1113, 1989.
41. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
42. Vázquez P, Roncero I, Blázquez E, Alvarez E. Substitution of the cysteine 438 residue in the cytoplasmic tail of the glucagon-like peptide-1 receptor alters signal transduction activity. J Endocrinol 185: 35-44, 2005.